Cagrilintide is a long-acting amylin analogue that reduces appetite and slows gastric emptying, whilst retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist designed to reduce appetite and increase energy expenditure
Keiser AA, Matazel KS, Esser MK, Feifel D, Prus AJ
Research from Russia and Eastern Europe, where DSIP has been studied more extensively than in the United States, has suggested the peptide may reduce withdrawal symptom severity and improve outcomes in opioid detoxification protocols
Retatrutide's triple-agonist mechanism produces higher weight loss than existing medications
This article may contain affiliate links, which means a commission may be earned if a purchase is made through such links at no additional cost to the reader
Funding This study was supported by grants from the Natural Science Foundation of Jiangsu Province (Grants No BK20171484), the Project of Invigorating Health Care through Science, Technology, and Education (Jiangsu Provincial Medical Youth Talent QNRC2016856), the National Natural Science Foundation of China (No
